SCHEMBL7510762

SCHEMBL7510762

COc1cc2ncnc(Cc3ccc(Br)cc3)c2cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 11/20 0.58
KDR P35968 4/20 0.58
ACHE P22303 1/20 0.52
BACE1 P56817 1/20 0.52
KDM4E B2RXH2 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HTT P42858 2/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPK1 P28482 3/20 0.50
ERBB2 P04626 2/20 0.50
STAT3 P40763 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
GAK O14976 1/20 0.50
MAPK13 O15264 1/20 0.50
ABL1 P00519 1/20 0.50
CYP1A2 P05177 1/20 0.50
CDK1 P06493 1/20 0.50
CYP3A4 P08684 1/20 0.50
FBP1 P09467 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19792401 0.87 KDM4E (0.62) EGFRKDRACHEBACE1KDM4E
SCHEMBL19797771 0.86 RET (0.56) EGFRKDRACHEKDM4EMEN1
SCHEMBL7516992 0.86 MAPK1 (0.63) EGFRKDRACHEBACE1KDM4E
SCHEMBL7512207 0.86 MAPK1 (0.62) EGFRACHEKDM4EMEN1KMT2A
SCHEMBL6183340 0.86 EGFR (0.61) EGFRKDRACHEBACE1KDM4E
SCHEMBL6273407 0.85 EGFR (0.57) EGFRKDRKDM4EHTTMAPK1
SCHEMBL7517324 0.83 KIT (0.60) EGFRKDRKDM4EMEN1KMT2A
SCHEMBL7510839 0.83 KIT (0.60) EGFRKDM4EMEN1KMT2AHTT
SCHEMBL18158153 0.82 EGFR (0.60) EGFRKDRKDM4EMEN1KMT2A
SCHEMBL7516352 0.81 MAPK1 (0.51) EGFRKDRACHEBACE1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0832073-B1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN INC (US) 2002-01-16 EP claimed
EP-0832073-B1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN INC (US) 2002-01-16 EP disclosed
US-6103728-A MODULATING TYROSINE SIGNAL TRANSDUCTION TO PREVENT AND TREAT CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES; ANTICARCINOGENIC,-TUMOR, PROLIFERATIVE AGENTS SUGEN, INC. (US) 2000-08-15 US disclosed
EP-0832073-A1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS Sugen, Inc. (US) 1998-04-01 EP disclosed
WO-1996040648-A1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN, INC. (US) 1996-12-19 WO disclosed